Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML

NCT00568633 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

58

Enrollment

OTHER

Sponsor class

Stopped Poor accrual

Conditions

Leukemia, Myeloid
Leukemia
Acute Myeloid Leukemia (AML)

Interventions

PROCEDURE: Allogeneic HSCT
DRUG: Anti-thymocyte globulin (ATG)
DRUG: Cyclosporine (CSP)
DRUG: Mycophenolate mofetil (MMF)
RADIATION: Total lymphoid irradiation (TLI)
DRUG: Methylprednisolone sodium succinate
DRUG: Best standard care

Sponsor

Stanford University

Collaborators

[object Object]